alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Research

27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.

Find studies

Showing 151–175 of 788 studies published 2014 (page 7 of 32) · 27,380 in the whole library · How the 0–100 score works

Download bibliography of the first 500 of these studies, in this order: BibTeX (.bib) · RIS (.ris)

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

Subjects

Authors

Names as each record prints them; the same person can appear under two spellings.

Institutions

From OpenAlex; 12,859 studies have no institution on record and are not counted here.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

Gender and incidence of dementia in the Framingham Heart Study from mid-adult life

✓ Peer-reviewed alzhub usefulness score 60 out of 100. Alzheimer's & dementia : the journal of the Alzheimer's Association 2014-01-10

Selective survival of men with a healthier cardiovascular risk profile and hence lower propensity to dementia might partly explain the higher LTR of dementia/AD in women. 1 key finding →

Participants: 7,901 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer's disease

✓ Peer-reviewed alzhub usefulness score 60 out of 100. Alzheimer s & Dementia 2014-05-02

There is increasing evidence that subjective cognitive decline (SCD) in individuals with unimpaired performance on cognitive tests may represent the first symptomatic manifestation of Alzheimer's disease (AD). 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Assessment of blood-brain barrier disruption using dynamic contrast-enhanced MRI. A systematic review

✓ Peer-reviewed alzhub usefulness score 60 out of 100. NeuroImage. Clinical 2014-09-10

There is increasing recognition of the importance of blood-brain barrier (BBB) disruption in aging, dementia, stroke and multiple sclerosis in addition to more commonly-studied pathologies such as tumors. 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source

Baseline neuropsychiatric symptoms and the risk of incident mild cognitive impairment: a population-based study

✓ Peer-reviewed alzhub usefulness score 60 out of 100. The American journal of psychiatry 2014-05-01

An increased incidence of mild cognitive impairment was observed in community-dwelling elderly adults who had nonpsychotic psychiatric symptoms at baseline. 3 key findings →

Design: cohort study Participants: 365 Evidence: moderate

Full summary, score breakdown and related studies → Original source

Multimorbidity and long-term care dependency--a five-year follow-up

✓ Peer-reviewed alzhub usefulness score 60 out of 100. BMC geriatrics 2014-05-28

The results should form the basis for future health policy decisions on the treatment of patients with multiple chronic diseases and also show the need to introduce new ways of providing long-term care to this population. 3 key findings →

Participants: 115,203 Evidence: moderate

Full summary, score breakdown and related studies → Original source

MAPT STUDY: A MULTIDOMAIN APPROACH FOR PREVENTING ALZHEIMER'S DISEASE: DESIGN AND BASELINE DATA

✓ Peer-reviewed alzhub usefulness score 59 out of 100. The journal of prevention of Alzheimer's disease 2014-06-01

AV45 PET scans were performed in 271 individuals and preliminary results showed that 38.0% had a cortical SUVR > 1.17, which gave an indication of significant brain amyloïd deposit. 1 key finding →

Participants: 1,680 Evidence: high

Full summary, score breakdown and related studies → Original source Free full text

Benefit-finding intervention for Alzheimer caregivers: conceptual framework, implementation issues, and preliminary efficacy

✓ Peer-reviewed alzhub usefulness score 59 out of 100. The Gerontologist 2014-03-31

Controlling for pretest, the benefit-finding group had lower depression than the psychoeducation group at post-test, despite the fact that some caregivers found benefit-finding challenging. 3 key findings →

Design: randomized controlled trial Evidence: high

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Optimizing patient care and research: the Amsterdam Dementia Cohort

✓ Peer-reviewed alzhub usefulness score 59 out of 100. Journal of Alzheimer's disease : JAD 2014-01-01

Since its opening in 2000, patient care and research go hand in hand at the Alzheimer center of the VU University Medical Center, both organized in such a way that they mutually strengthen each other. 1 key finding →

Participants: 4,000 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

The main cost drivers in dementia: a systematic review

✓ Peer-reviewed alzhub usefulness score 59 out of 100. International journal of geriatric psychiatry 2014-10-16

The results of this review highlight the significant economic burden of dementia for patients, families and healthcare systems and thus are important for future health policy planning. 5 key findings →

Design: systematic review Evidence: high

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Widespread grey matter pathology dominates the longitudinal cerebral MRI and clinical landscape of amyotrophic lateral sclerosis

✓ Peer-reviewed alzhub usefulness score 59 out of 100. Brain : a journal of neurology 2014-06-20

Longitudinal analysis revealed progressive and widespread changes in the grey matter, notably including the basal ganglia. 4 key findings →

Design: cross-sectional Participants: 36 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Sensor-derived physical activity parameters can predict future falls in people with dementia

✓ Peer-reviewed alzhub usefulness score 59 out of 100. Gerontology 2014-08-28

Surprisingly, fallers and non-fallers did not differ on any conventional assessment (p = 0.069-0.991), except for 'previous faller' (p = 0.006). 5 key findings →

Design: cohort study Participants: 77 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Pharmacological treatment of Parkinson disease: a review

✓ Peer-reviewed alzhub usefulness score 59 out of 100. JAMA 2014-04-01

Although levodopa is the most effective medication available for treating the motor symptoms of Parkinson disease, in certain instances (eg, mild symptoms, tremor as the only or most prominent symptom, aged Conclusions and relevance Strong evidence supports using levodopa and dopamine agonists for motor symptoms at all stages of Parkinson disease. 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Body fluid cytokine levels in mild cognitive impairment and Alzheimer's disease: a comparative overview

✓ Peer-reviewed alzhub usefulness score 59 out of 100. Molecular neurobiology 2014-02-25

This article gives a comprehensive overview of cytokine and other inflammation associated protein levels in plasma, serum and cerebrospinal fluid (CSF) of patients with Alzheimer's disease (AD) and mild cognitive impairment (MCI). 2 key findings →

Design: longitudinal study Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Cognitive changes preceding clinical symptom onset of mild cognitive impairment and relationship to ApoE genotype

✓ Peer-reviewed alzhub usefulness score 59 out of 100. Current Alzheimer research 2014-01-01

Cognitive changes in normal individuals who will subsequently decline may be observed at least 6.5 years prior to symptom onset. 1 key finding →

Design: longitudinal study Participants: 208 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Infection management and multidrug-resistant organisms in nursing home residents with advanced dementia

✓ Peer-reviewed alzhub usefulness score 59 out of 100. JAMA internal medicine 2014-10-01

The cohort experienced 496 suspected infections; 72.4% were treated with antimicrobials, most commonly quinolones (39.8%) and third- or fourth-generation cephalosporins (20.6%). 3 key findings →

Design: cohort study Evidence: moderate

Full summary, score breakdown and related studies → Original source

Comparison of sertraline, venlafaxine and desipramine effects on depression, cognition and the daily living activities in Alzheimer patients

✓ Peer-reviewed alzhub usefulness score 58 out of 100. Pharmacopsychiatry 2014-06-23

The effects of antidepressants on mood, cognition and the daily activities of Alzheimer patients are ambiguous. 1 key finding →

Evidence: high

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Is sertraline treatment or depression remission in depressed Alzheimer patients associated with improved caregiver well being? Depression in Alzheimer's Disease Study 2

✓ Peer-reviewed alzhub usefulness score 58 out of 100. The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry 2014-01-01

Patient treatment with sertraline was not associated with significantly greater reductions in caregiver distress than placebo treatment. 5 key findings →

Participants: 131 Evidence: high

Full summary, score breakdown and related studies → Original source Free full text

Cerebrospinal fluid levels of the synaptic protein neurogranin correlates with cognitive decline in prodromal Alzheimer's disease

✓ Peer-reviewed alzhub usefulness score 58 out of 100. Alzheimer's & dementia : the journal of the Alzheimer's Association 2014-12-19

Synaptic dysfunction is an early event in Alzheimer's disease (AD) pathogenesis and directly related to cognitive impairment. 1 key finding →

Participants: 100 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomised / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multi-centre collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed